Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;20(10):1294-1304.
doi: 10.1038/s41589-024-01583-8. Epub 2024 Mar 20.

Sulfide oxidation promotes hypoxic angiogenesis and neovascularization

Affiliations

Sulfide oxidation promotes hypoxic angiogenesis and neovascularization

Roshan Kumar et al. Nat Chem Biol. 2024 Oct.

Abstract

Angiogenic programming in the vascular endothelium is a tightly regulated process for maintaining tissue homeostasis and is activated in tissue injury and the tumor microenvironment. The metabolic basis of how gas signaling molecules regulate angiogenesis is elusive. Here, we report that hypoxic upregulation of ·NO in endothelial cells reprograms the transsulfuration pathway to increase biogenesis of hydrogen sulfide (H2S), a proangiogenic metabolite. However, decreased H2S oxidation due to sulfide quinone oxidoreductase (SQOR) deficiency synergizes with hypoxia, inducing a reductive shift and limiting endothelial proliferation that is attenuated by dissipation of the mitochondrial NADH pool. Tumor xenografts in whole-body (WBCreSqorfl/fl) and endothelial-specific (VE-cadherinCre-ERT2Sqorfl/fl) Sqor-knockout mice exhibit lower mass and angiogenesis than control mice. WBCreSqorfl/fl mice also exhibit decreased muscle angiogenesis following femoral artery ligation compared to control mice. Collectively, our data reveal the molecular intersections between H2S, O2 and ·NO metabolism and identify SQOR inhibition as a metabolic vulnerability for endothelial cell proliferation and neovascularization.

PubMed Disclaimer

Update of

References

    1. Carmeliet P. Angiogenesis in health and disease. Nat Med 9, 653–60 (2003). - PubMed
    1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438, 932–6 (2005). - PubMed
    1. Folkman J. Angiogenesis. Annu Rev Med 57, 1–18 (2006). - PubMed
    1. Hurwitz H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350, 2335–42 (2004). - PubMed
    1. Ribatti D, Annese T, Ruggieri S, Tamma R & Crivellato E Limitations of Anti-Angiogenic Treatment of Tumors. Transl Oncol 12, 981–986 (2019). - PMC - PubMed

LinkOut - more resources